Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus fulvestrant
cediranib plus fulvestrant
NCT00454805, 2013
  NCT00454805
RCTla/mBC - HR-positive - 1st line (L1)cediranib plus fulvestrantfulvestrantPostmenopausal women with histologically/cytologically confirmed hormone-sensitive BC, with evidence of metastatic disease.-/-high
inconclusive
  • inconclusive 13 % decrease in progression or deaths (PFS) (PE)